Peptide therapy TikTok claims: separating hype from actual evidence

What did @guyver210 actually say?

Almost nothing of substance, honestly. The entire transcript is account housekeeping. The creator references "this chart here" about peptides and promises it "better tell you the answers to all these questions," but the actual spoken content is entirely about a hacked TikTok account, asking for follows, and frustration with TikTok support. No specific peptide claims are made in the audio we can evaluate.

This matters because 142,700 people watched this video. A significant portion of them are presumably here for peptide information. What they got instead was a visual chart that we cannot verify from the transcript alone, paired with zero verbal context, no cited sources, and no explanation of the data being presented. That is not education. That is vibes with a graphic overlay.

Does the science back this up?

There is no spoken scientific claim to evaluate here. What we can do is flag what peptide charts on social media typically assert, and how poorly those assertions usually hold up to scrutiny.

Peptides like BPC-157, TB-500, CJC-1295, and ipamorelin are frequently presented in grid-format charts with dosing protocols, stacking recommendations, and healing timelines. The problem is that most of the human data on these compounds is either preliminary, nonexistent, or derived from animal models that do not translate cleanly to human physiology. BPC-157, for example, has shown tissue repair effects in rodent models (Sikiric et al., 2018, Current Pharmaceutical Design), but as of 2024 there are no completed Phase III clinical trials in humans. TB-500's active fragment thymosin beta-4 has similarly limited human trial data. Any chart presenting these compounds with confident dosing grids is outrunning the evidence considerably.

What did they get wrong (or right)?

There is nothing in the spoken transcript to fact-check as right or wrong. The creator got one thing correct by default: TikTok account recovery is genuinely unreliable, and that part of the video is accurate.

The concern here is structural, not factual. Presenting a peptide chart without verbal explanation, sourcing, or clinical context is a format that implicitly signals authority while providing none. Viewers who screenshot and act on unsourced peptide dosing charts have no way to evaluate whether the information reflects research consensus, a vendor's recommendations, or something a forum user posted in 2019. That gap between perceived credibility and actual evidentiary basis is where people get hurt. Peptides like MK-677 (ibutamoren), which is often grouped with peptides but is actually a small molecule ghrelin mimetic, carry real risks including insulin resistance and fluid retention that a chart without nuance will not communicate (Nass et al., 2008, Journal of Clinical Endocrinology and Metabolism).

What should you actually know?

Peptide therapy is a genuinely interesting area of research. Some compounds have real mechanistic plausibility and early-stage data worth paying attention to. But the gap between "interesting research compound" and "here is your dosing chart" is enormous, and social media collapses that gap constantly.

If you are considering peptide therapy, the relevant questions are not answered by a TikTok chart. You need to know whether a compound is FDA-approved, compounded, or research-grade, because those categories have completely different safety and purity implications. You need a provider who can evaluate your bloodwork, not a screenshot. GHK-Cu, semax, and selank, for instance, are not FDA-approved for any indication and are not legal to prescribe in a clinical context in the same way licensed therapeutics are. That does not mean the research is worthless. It means the path from research to your body requires more than a follow and a save.

• Always ask whether the compound has human clinical trial data, not just animal studies.
• Compounded peptides vary significantly in purity depending on the pharmacy. Regulatory oversight matters here.
• A provider who refuses to discuss risks alongside benefits is not a provider worth trusting.